SCHEMBL5359305

SCHEMBL5359305

Cc1ccc(CN2CCC(CNC(=O)c3ccc(O)cc3)CC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.73
CACNA1I Q9P0X4 1/20 0.73
HDAC3 O15379 4/20 0.64
HDAC4 P56524 4/20 0.64
HDAC1 Q13547 4/20 0.64
HDAC7 Q8WUI4 4/20 0.64
HDAC2 Q92769 4/20 0.64
HDAC10 Q969S8 4/20 0.64
HDAC11 Q96DB2 4/20 0.64
HDAC8 Q9BY41 4/20 0.64
HDAC6 Q9UBN7 4/20 0.64
HDAC9 Q9UKV0 4/20 0.64
HDAC5 Q9UQL6 4/20 0.64
UBE2N P61088 1/20 0.61
CHRM4 P08173 2/20 0.58
HTR4 Q13639 1/20 0.56
GAA P10253 1/20 0.56
CCR2 P41597 3/20 0.55
MCHR1 Q99705 1/20 0.54
MEN1 O00255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368040 0.89 CCR2 (0.69) KCNH2CACNA1IHDAC3HDAC4HDAC1
SCHEMBL5368811 0.88 HDAC3 (0.64) KCNH2CACNA1IHDAC3HDAC4HDAC1
SCHEMBL5371060 0.88 HDAC3 (0.82) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6207518 0.86 KCNH2 (0.68) KCNH2CACNA1IHDAC3HDAC4HDAC1
SCHEMBL14425271 0.83 CCR2 (0.53) KCNH2CACNA1IHDAC3HDAC4HDAC1
SCHEMBL5366982 0.83 CCR2 (0.53) KCNH2CACNA1IHDAC3HDAC4HDAC1
SCHEMBL8315153 0.82 HDAC3 (0.69) KCNH2CACNA1IHDAC3HDAC4HDAC1
SCHEMBL5368197 0.82 TPSAB1 (0.72) KCNH2CACNA1I
SCHEMBL5378277 0.81 HDAC3 (0.71) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL28361506 0.81 KCNH2 (0.66) KCNH2CACNA1IHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259157-B2 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK & CO., INC. (US) 2007-08-21 US disclosed
US-7259157-B2 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK & CO., INC. (US) 2007-08-21 US disclosed
US-7259157-B2 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK & CO., INC. (US) 2007-08-21 US disclosed
EP-1390034-A4 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2005-07-13 EP disclosed
EP-1390034-A1 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2004-02-25 EP disclosed
US-20030119811-A1 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK SHARP & DOHME CORP. 2003-06-26 US disclosed
WO-2002080928-A1 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119811-A1 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists GRIN1, GRIN2B, GRIN2A KCNH2 252/4885CACNA1I 58/4885HDAC3 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.